Form S-8 - Securities to be offered to employees in employee benefit plans:
SEC Accession No. 0000950170-25-046168
Filing Date
2025-03-27
Accepted
2025-03-27 16:53:22
Documents
6
Effectiveness Date
2025-03-27

Document Format Files

Seq Description Document Type Size
1 S-8 s-8_evergreen_mar_2025.htm S-8 157623
2 EX-5.1 kytx-ex5_1.htm EX-5.1 28815
3 EX-23.1 kytx-ex23_1.htm EX-23.1 4212
4 EX-FILING FEES kytx-exfiling_fees.htm EX-FILING FEES 44809
5 GRAPHIC img89746796_0.jpg GRAPHIC 28888
6 GRAPHIC img89746796_1.jpg GRAPHIC 11290
  Complete submission text file 0000950170-25-046168.txt   292145
Mailing Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608
Business Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608 5106268331
Kyverna Therapeutics, Inc. (Filer) CIK: 0001994702 (see all company filings)

EIN.: 831365441 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-8 | Act: 33 | File No.: 333-286181 | Film No.: 25780167
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)